Harvard Bioscience (HBIO) traded down -1.32 % during a 24 hours period ending at 11:00 PM Central Europe on Monday 26th. One Harvard Bioscience stock can currently be bought for about USD 8.32 on popular exchanges. Current supply of Harvard Bioscience stocks is 4.6 mn. Harvard Bioscience has a current market capitalization of USD 37.5 mn and approximately USD 222.2 k worth of Harvard Bioscience was traded on exchanges in the last 24 hours. Since last month end, Harvard Bioscience has traded 2.62 % up. Simple moving average of last 200 days is at USD 6.38. The highest price of past 52 weeks was recorded at USD 9.4 on 10/30/2025. 52 weeks low was at USD 4 on 03/12/2026.

Here is how related stocks have performed in the past 24 hours:

  • Solitario (XPL) traded up 6.38 % and now trades at USD 0.49. Solitario has a market capitalisation of USD 44.5 mn.

  • Vulcan Infrastructure And Po (VIP) traded down -0.79 % and now trades at USD 1.26. Vulcan Infrastructure And Po has a market capitalisation of USD 44.5 mn. Current price/earnings ratio for Vulcan Infrastructure And Po is 50.79. VULCAN INFRASTRUCTURE AND PO has issued a brief statement concerning recent market activity. The company noted that its share performance has remained relatively stable, with minor fluctuations observed during the latest trading sessions. Management emphasized continued focus on infrastructure development projects and highlighted ongoing efforts to strengthen operational efficiency. No immediate changes to strategic plans or financial outlook were disclosed, and the company reiterated its commitment to delivering consistent value to investors.

  • Sanuwave Health (SNWV) traded down -1.51 % and now trades at USD 5.07. Sanuwave Health has a market capitalisation of USD 44.9 mn.

  • Forum Markets (FRMM) traded up 1.5 % and now trades at USD 3.38. Current market capitalisation for Forum Markets is USD 44.6 mn.

  • Kalaris Therapeutics (KLRS) traded down -6.03 % and now trades at USD 1.8. Current market capitalisation for Kalaris Therapeutics is USD 44.5 mn.

About Harvard Bioscience

Harvard Bioscience, Inc. is a health care company that specializes in developing, manufacturing, and marketing tools essential for drug discovery research in pharmaceutical and biotechnology companies, universities, and government laboratories. The company offers proteomics products that assist researchers in purifying and analyzing proteins, and ADMET screening products that test potential drug candidates. Their webseite is www.harvardbioscience.com , and they are listed on the Nasdaq stock exchange. Their IPO date is December 7, 2000.